Publicaciones en colaboración con investigadores/as de Medical University of Vienna (5)

2022

  1. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Blood, Vol. 140, Núm. 8, pp. 839-850

  2. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

2020

  1. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study

    Journal of Clinical Oncology

2018

  1. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia

    New England Journal of Medicine, Vol. 378, Núm. 12, pp. 1107-1120

2016

  1. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

    Leukemia, Vol. 30, Núm. 9, pp. 1844-1852